Formulation and Evaluation of Verapamil Hydrochloride Sustain Release Tablet

Verapamil hydrochloride, a calcium channel blocker, is used to treat hypertension, supraventricular arrhythmia and myocardial infarction Verapamil hydrochloride (VPH) sustain release tablets were developed for this study in order to maintain plasma concentrations, enhance bioavailability, and avoid repeated dosing. Materials and procedures Tablets containing a fixed amount of VPH were made using the direct compression method and various combinations and ratios of the polymers hydroxypropyl methyl cellulose (HPMC K15) and ethyl cellulose. The tablets were then tested for thickness, weight variation, hardness, uniformity of the drug content, drug release, and potential ingredient interactions. Regarding thickness, weight variation, hardness, and medication content, all tablets were satisfactory. It may be determined from formulations comprising HPMCK15 and ethyl cellulose that the two polymers functioned well together, controlling the first burst and improving the drug's release throughout the first three hours. A study of in vitro drug release followed the formulation of the 32 factorial planned batches. The formulations F5, F6, and F8 demonstrated better drug release up to 24hours and minimal burst release with more than 80% release in 24hours. They were composed of HPMC K15 60mg, 60 mg, and 75mg, respectively, and ethyl cellulose 30mg, 45mg, and 30mg, respectively. Thus, the F5 formulation with somewhat lower polymer content was chosen as the optimal formulation and they contained HPMC K15 60mg and ethyl cellulose 30mg.